1h Free Analyst Time
The publisher's latest disease pipeline guide Actinic (Solar) Keratosis - Drugs In Development, 2022, provides an overview of the Actinic (Solar) Keratosis (Dermatology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
An actinic keratosis, also known as a solar keratosis, is a scaly or crusty growth (lesion). It most often appears on the bald scalp, face, ears, lips, backs of the hands and forearms, shoulders, neck or any other areas of the body frequently exposed to the sun. The signs and symptoms of an actinic keratosis include a hard, wart-like surface, patch or bump on the top layer of skin, itching or burning in the affected area and color as varied as pink, red or brown, or flesh-colored. The predisposing factors include age, sunny climate, history of frequent or intense sun exposure or sunburn, pale skin, red or blond hair, and blue or light-colored eyes and a weak immune system as a result of chemotherapy, chronic leukemia, AIDS or organ transplant medications.
Report Highlights
The publisher's latest pipeline guide Actinic (Solar) Keratosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Actinic (Solar) Keratosis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Actinic (Solar) Keratosis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Actinic (Solar) Keratosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 1, 1, 6, 2, 1, 7 and 2 respectively.
Actinic (Solar) Keratosis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Actinic (Solar) Keratosis (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Actinic (Solar) Keratosis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Actinic (Solar) Keratosis (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Actinic (Solar) Keratosis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Actinic (Solar) Keratosis (Dermatology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Actinic (Solar) Keratosis (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Actinic (Solar) Keratosis (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of TablesList of Figures
Introduction
Report Coverage
Actinic (Solar) Keratosis - Overview
Actinic (Solar) Keratosis - Therapeutics Development
Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
Assesement by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Actinic (Solar) Keratosis - Companies Involved in Therapeutics Development
Actinic (Solar) Keratosis - Drug Profiles
Actinic (Solar) Keratosis - Dormant Projects
Actinic (Solar) Keratosis - Discontinued Products
Actinic (Solar) Keratosis - Product Development Milestones
Featured News
Feb 18, 2022: Jupiter Wellness completes enrollment in double-blind placebo-controlled clinical trial of JW-200 for the treatment of actinic keratosis
Oct 14, 2021: Indicative announcement aminolevulinic acid hydrochloride topical powder received the acceptance notice for the investigational new drug application
Sep 27, 2021: Almirall launches Klisyri(Tirbanibulin) for the treatment of actinic keratosis in Europe
Sep 20, 2021: Vidac Pharma announces wider spectrum authorization of its CTCL phase 2 clinical trial
Jul 19, 2021: Almirall receives European Commission approval of Klisyri (tirbanibulin), an innovative topical treatment for actinic keratosis
May 21, 2021: Almirall receives positive CHMP opinion for Klisyri (tirbanibulin), an innovative topical treatment for actinic keratosis
Feb 18, 2021: Almirall U.S. launches Klisyri (tirbanibulin), a new, innovative topical treatment for actinic keratosis
Feb 18, 2021: Athenex announces U.S. launch of Klisyri and licensing of additional territories for tirbanibulin
Feb 11, 2021: Athenex announces New England Journal of Medicine publication of phase III data on the efficacy and safety of Klisyri (tirbanibulin)
Dec 15, 2020: Almirall announces FDA approval of Klisyri (tirbanibulin), a new innovative topical treatment for actinic keratosis
Mar 09, 2020: Athenex announces FDA acceptance for filing of U.S. NDA for tirbanibulin ointment in actinic keratosis
Mar 02, 2020: Athenex’s partner Almirall announces EMA acceptance for filing of Marketing Authorization Application (MAA) for tirbanibulin ointment in actinic keratosis
Oct 28, 2019: Athenex announces progress update from partner Almirall on Tirbanibulin Ointment
Mar 04, 2019: Athenex announces positive topline results from two phase III studies of KX2-391 ointment 1% featured in late breaker program at the 2019 American Academy of Dermatology Annual Meeting
Feb 25, 2019: Athenex to host conference call with key opinion leader following oral presentation of phase III results of KX2-391 ointment in the treatment of actinic keratosis at the American Academy of Dermatology Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
- Number of - Products under Development for Actinic (Solar) Keratosis, 2022
- Number of - Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
Actinic (Solar) Keratosis - Pipeline by Claradele Pharmaceuticals Inc, 2022
Actinic (Solar) Keratosis - Pipeline by Coegin Pharma AS, 2022
Actinic (Solar) Keratosis - Pipeline by G&E Herbal Biotechnology Co., Ltd., 2022
Actinic (Solar) Keratosis - Pipeline by Ingenew Pharmaceuticals Inc, 2022
Actinic (Solar) Keratosis - Pipeline by Invion Ltd, 2022
Actinic (Solar) Keratosis - Pipeline by Jupiter Wellness Inc, 2022
Actinic (Solar) Keratosis - Pipeline by Laboratories Ojer Pharma SL, 2022
Actinic (Solar) Keratosis - Pipeline by MedC Biopharma Ltd, 2022
Actinic (Solar) Keratosis - Pipeline by MediWound Ltd, 2022
Actinic (Solar) Keratosis - Pipeline by Nanology LLC, 2022
Actinic (Solar) Keratosis - Pipeline by Neonc Technologies Inc, 2022
Actinic (Solar) Keratosis - Pipeline by Oncology Research International Ltd, 2022
Actinic (Solar) Keratosis - Pipeline by Ponce Therapeutics Inc, 2022
Actinic (Solar) Keratosis - Pipeline by Provectus Biopharmaceuticals Inc, 2022
Actinic (Solar) Keratosis - Pipeline by RepoCeuticals ApS, 2022
Actinic (Solar) Keratosis - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, 2022
Actinic (Solar) Keratosis - Pipeline by Singh Biotechnology LLC, 2022
Actinic (Solar) Keratosis - Pipeline by Sol-Gel Technologies Ltd, 2022
Actinic (Solar) Keratosis - Pipeline by Vidac Pharma, 2022
Actinic (Solar) Keratosis - Dormant Projects, 2022
Actinic (Solar) Keratosis - Dormant Projects, 2022 (Contd..1)
Actinic (Solar) Keratosis - Dormant Projects, 2022 (Contd..2)
Actinic (Solar) Keratosis - Discontinued Products, 2022 List of Figures
- Number of - Products under Development for Actinic (Solar) Keratosis, 2022
- Number of - Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Athenex Inc
- Claradele Pharmaceuticals Inc
- Coegin Pharma AS
- G&E Herbal Biotechnology Co., Ltd.
- Ingenew Pharmaceuticals Inc
- Invion Ltd
- Jupiter Wellness Inc
- Laboratories Ojer Pharma SL
- MedC Biopharma Ltd
- MediWound Ltd
- Nanology
